Pfizer, GSK expand discount pneumococcal vaccine agreements with GAVI
This article was originally published in Scrip
Executive Summary
Pfizer and GlaxoSmithKline are broadening their agreements with the vaccine-funder GAVI Alliance, which is a public-private initiative. Each has agreed to provide hundreds of millions of additional doses of their pneumococcal vaccine at a small fraction of developed world prices.